BHIVA Autumn Conference

13–14 October 2016
QEII Centre
London

including

CHIVA Parallel Sessions

Friday 14 October 2016

Preceded by

Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection
in collaboration with the British Viral Hepatitis Group (BVHG)
Wednesday 12 October 2016

www.bhiva.org
Joining forces, changing futures
HIV in women: science, stigma and society

Please join us at 09:00 on Thursday 13th October in the Fleming Hall where our panel will be discussing the inequalities faced by women living with HIV, from socio-cultural aspects, including domestic abuse and stigma through to the imbalance seen with female representation in clinical trials.

Thursday 13th October, 09:00–10:00
Fleming Hall, Queen Elizabeth II Conference Centre, London

Chaired by Dr Annemieke de Ruiter
Honorary consultant in HIV medicine at Guy’s and St Thomas’ NHS Foundation Trust
Senior Global Medical Director, ViiV Healthcare

Symposium speakers:
Dr Sara Paparini
Research Fellow, London School of Hygiene and Tropical Medicine
Paula Evenden
Co-Director, Dragonfly Collective

Dr Paul Benn
Honorary consultant in HIV medicine at Mortimer Market
European Medical Team, ViiV Healthcare

Prescribing Information

Truvada®/Tivicay® dolutegravir 50mg/abacavir 600mg/ lamivudine 300mg tablets
See Summary of Product Characteristics before prescribing. Indication: HIV in over 12 years and a WHO Score for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. Once: one tablet once daily with or without food. Elderly: limited data in 65+ yrs. Creatinine >150 μmol/L: reduction in dosage and consider metformin dose adjustment. Warning/precautions: Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701 or previous suspected and/or HSR. Stop Truvada without delay if HSR suspected. Never reintroduce any abacavir- or dolutegravir-containing product after suspected HSR. Risks of immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C combination therapy. Inconclusive data on relationship between abacavir and MI, minimise all modifiable CV risk factors (e.g. smoking, hyperlipidaemia, hypertension). Not recommended if dolutegravir required but both known HIV mutations (e.g. M184V) missed.

Triumeq® dolutegravir 50mg/abacavir 600mg/ lamivudine 300mg tablets

Truvada is a registered trademark of the ViiV Healthcare Group of Companies.

Tivicay is a registered trademark of the ViiV Healthcare Group of Companies.

Date of approval: July 2016

Zinc code: UK/TRA/MED/14/189

Zinc code: UK/DLG/0055/13(7)

Zinc code: UK/TRA/MED/14/183

Zinc code: UK/TRA/MED/14/180

Basic NHS costs: £498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Triumeq is a registered trademark of the ViiV Healthcare Group of Companies.

Date of approval: August 2015

Zinc code: UK/TRA/MS/12/175

Dosing:
Triumeq is a combination therapy.

Basic NHS costs:
£498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Basic NHS costs:
£498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Basic NHS costs:
£498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Basic NHS costs:
£498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Truvada is a registered trademark of the ViiV Healthcare Group of Companies.

Tivicay is a registered trademark of the ViiV Healthcare Group of Companies.

Date of approval: August 2015

Zinc code: UK/TRA/MS/12/175

Dosing:
Triumeq is a combination therapy.

Basic NHS costs:
£498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Basic NHS costs:
£498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Basic NHS costs:
£498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Basic NHS costs:
£498.75 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 100 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Truvada is a registered trademark of the ViiV Healthcare Group of Companies.

Tivicay is a registered trademark of the ViiV Healthcare Group of Companies.
Dear Colleague

Welcome to the BHIVA Autumn Conference preceded by the Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection. Again, both conferences are held at a prestigious conference centre in the heart of London.

I would like to thank Chloe Orkin (Chair of the Conferences Subcommittee), Sanjay Bhagani (Chair of the BHIVA Hepatitis Society), Caroline Sabin (Conference Local Host) and all the members of the Conferences Subcommittee for their efforts in preparing an excellent programme for this conference. In addition, we are delighted to once again, hold parallel sessions on Friday in collaboration with the Children’s HIV Association (CHIVA).

The conference sessions will cover a wide range of important topics relevant to HIV. Please refer to the programme pages for a full schedule of topics and timings.

The BHIVA Annual General Meeting will be held on Friday 14 October prior to lunch. I would encourage all BHIVA members to attend this meeting as it provides a forum to present any points they may have to the BHIVA Officers and members of the Executive Committee.

Finally, we would like to thank our sponsors for their continued support of the Association, which assists greatly with covering some of the costs incurred in organising this conference.

We very much hope you enjoy the programme and find it relevant to both your educational and practical needs.

Dr David Asboe
Chair, British HIV Association
**EXECUTIVE COMMITTEE**

**OFFICERS**

**Chair**
Dr C Orkin  
Chelsea and Westminster Hospital, London

**Vice Chair**
Dr L Waters  
Leicester Royal Infirmary

**Honorary Treasurer**
Dr D Asboe  
Royal Sussex County Hospital, Brighton

**MEMBERS**

Prof B Angus  
University of Oxford

Prof M Bower  
Chelsea and Westminster Hospital, London

Dr D Chadwick  
James Cook University Hospital, Middlesbrough

Dr M Chaponda  
Royal Liverpool University Hospital

Mr P Clift  
UK-CAB Community Representative

Prof L Dorrell  
University of Oxford

Dr A Freedman  
Cardiff University School of Medicine

Prof B Gazzard CBE  
Chelsea and Westminster Hospital, London

Dr Y Gilleece  
Royal Sussex County Hospital, Brighton

Prof C Leen  
Western General Hospital, Edinburgh

Dr C Orkin  
Barts Health NHS Trust, London

Dr I Reeves  
Homerton University Hospital, London

Prof C Sabin  
University College London

Dr G Schembri  
Manchester Centre for Sexual Health

Dr A Sullivan  
Chelsea and Westminster Hospital, London

Dr L Waters  
Mortimer Market Centre, London

**CONFERENCES SUBCOMMITTEE**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr C Orkin</td>
<td>Chair and BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr L Waters</td>
<td>Vice Chair and BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Prof C Sabin</td>
<td>BHIVA Local Host and Education and Scientific Subcommittee Chair</td>
</tr>
<tr>
<td>Dr D Asboe</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Prof M Bower</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Mr G Brough</td>
<td>Invited Representative</td>
</tr>
<tr>
<td>Dr D Churchill</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr M Chaponda</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Mr P Clift</td>
<td>BHIVA Executive Committee member and Community Representative</td>
</tr>
<tr>
<td>Prof B Gazzard CBE</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Prof C Leen</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Mrs S Morris</td>
<td>Invited Representative</td>
</tr>
<tr>
<td>Dr A Palfreeman</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr I Reeves</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr G Schembri</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr M Tenant-Flowers</td>
<td>Invited Representative</td>
</tr>
<tr>
<td>Dr E Wilkins</td>
<td>Invited Representative</td>
</tr>
</tbody>
</table>

**BHIVA HEPATITIS SOCIETY EXECUTIVE PANEL**

**Chair**
Dr S Bhagani  
Royal Free London NHS Foundation Trust

**Vice Chair**
Prof M Nelson  
Chelsea and Westminster Hospital, London

**MEMBERS**

Dr K Agarwal  
King's College Hospital NHS Trust, London

Dr D Asboe  
Chelsea and Westminster Hospital, London

Dr A Brown  
Imperial College Healthcare NHS Trust, London

Dr D Chadwick  
James Cook University Hospital, Middlesbrough

Dr G Cooke  
Imperial College London

Prof G Foster  
Queen Mary University of London

Dr A Freedman  
Cardiff University School of Medicine

Dr R Kulasegaram  
St Thomas' Hospital, London

Prof C Leen  
Western General Hospital, Edinburgh

Dr C Orkin  
Barts Health NHS Trust, London

Dr E Thomson  
University of Glasgow

Dr A Ustianowski  
Chair of BVHG, North Manchester General Hospital

Dr E Wilkins  
North Manchester General Hospital

Mr R James  
Birchgrove
PROGRAMME SUMMARY

WEDNESDAY 12 OCTOBER 2016

Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection in collaboration with BVHG

0830–1830  Registration and Exhibition open
0855–0900  Welcome Address
0900–1100  Session 1
1100–1130  Morning coffee
1130–1230  Gilead Sciences Satellite Symposium
1230–1330  Session 2
1330–1430  Lunch
1430–1610  Session 3
1610–1630  Afternoon tea
1630–1730  Plenary Session 4
1730–1800  Keynote Lecture
1800  Close

THURSDAY 13 OCTOBER 2016

BHIVA Autumn Conference

0830–1830  Registration and exhibition open
0855–0900  Welcome Address
0900–1000  ViiV Healthcare UK Satellite Symposium
1000–1030  BHIVA Foundation Lecture
1030–1100  Morning coffee
1100–1200  BHIVA Guidelines Session
1200–1230  BHIVA Audit Session
1230–1400  Lunch
1240–1325  BHIVA Lunchtime Workshop
1255–1355  Janssen Lunchtime Workshop
1400–1500  BHIVA Plenary Session 1
1500–1600  BHIVA Plenary Session 2
1600–1630  Afternoon tea
1630–1730  BHIVA Plenary Session 3
1730–1830  Pfizer Ltd Satellite Symposium
1830–1930  Drinks Reception

FRIDAY 14 OCTOBER 2016

BHIVA Autumn Conference  CHIVA Parallel Sessions

0815–1440  Registration and exhibition open
0900–1000  Gilead Sciences Satellite Symposium  Parallel Session 1
1000–1030  Gazzard Lectureship in HIV Medicine
1030–1040  BHIVA Awards Ceremony
1040–1110  Morning coffee
1110–1140  BHIVA Plenary Lecture  Parallel Session 2
1140–1310  BHIVA Best Practice Management Session
1310–1340  BHIVA Annual General Meeting
1310–1440  Lunch
1345–1430  BHIVA Lunchtime Workshop
1440–1540  BHIVA Community Symposium  Parallel Session 3
1540–1640  BHIVA Clinical Conundrums
1640–1645  Close
**PROGRAMME**

**WEDNESDAY 12 OCTOBER 2016**

**Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection**

in collaboration with the British Viral Hepatitis Group (BVHG)

---

**0830–1830** Registration and exhibition open

**0855–0900** Welcome and Introduction Churchill, Ground Floor

Dr Sanjay Bhagani  
*Royal Free London NHS Foundation Trust*

Dr Andrew Ustianowski  
*North Manchester General Hospital*

**0900–1100** Session 1: Advances in viral hepatitis management: Bench to clinic

**Chairs:**  
Dr Ashley Brown  
*Imperial College Healthcare NHS Trust, London*

Dr Chloe Orkin  
*Barts Health NHS Trust, London*

**Upcoming HCV therapy and ‘difficult-to-treat patients’**

Professor Graham Foster  
*Queen Mary University of London*

**Resistance testing in HCV infection – is it necessary?**

Professor Jean-Michel Pawlotsky  
*Hôpital Henri-Mondor, Paris, France*

**New paradigms in HBV management**

Professor Geoff Dusheiko  
*Royal Free London NHS Foundation Trust*

**Panel discussion**

**1100–1130** Morning coffee

**1130–1230**  
**Gilead Sciences Satellite Symposium**  
(See page 14 for further information)

**1230–1330** Session 2: HIV/Hepatitis co-infection clinical case presentations

**Facilitators:**  
Dr Ranjababu Kulasegaram  
*Guy’s and St Thomas’ NHS Foundation Trust, London*

Dr Emma Thomson  
*University of Glasgow*

**Case report: a treatment dilemma**

Dr Chris Dugan  
*Royal Free London NHS Foundation Trust*

**Fallen at the first hurdle**

Dr Sarah Ramsay  
*Barts Health NHS Trust, London*

**A wild goose chase**

Dr Diarmuid Nugent  
*Mortimer Market Centre, London*

**1330–1430** Lunch

**1430–1610** Session 3: UK CHIC Viral Hepatitis Programme

**Chairs:**  
Dr Sanjay Bhagani  
*Royal Free London NHS Foundation Trust*

Dr Andrew Ustianowski  
*North Manchester General Hospital*
Introduction
Professor Caroline Sabin
University College London

Summary of ongoing/completed UK CHIC work

Update on the epidemiology of HBV/HCV in the UK CHIC cohort
Ms Alicia Thornton
University College London

Treatment uptake and outcomes for HCV
Dr Richard Gilson
University College London

ESLD: referral for transplantation and outcomes
Dr Charlotte Warren-Gash
University College London

Looking forwards: how can we benefit with wider collaborations?

HCV research/stop HCV
Professor William Irving
University of Nottingham

Modelling work
Professor Peter Vickerman
University of Bristol

Collaborations with PHE
Dr Ruth Simmons
Public Health England

Panel discussion

1610–1630 Afternoon tea

1630–1730 Session 4: Non-viral Liver Disease
Chairs: Dr Graham Cooke
Imperial College London

Dr Yvonne Gilleece
Royal Sussex County Hospital, Brighton

Non-alcoholic fatty liver: a practical approach
Professor Mark Thursz
University College London

How important is alcohol as a contributor to liver disease in patients with viral hepatitis and HIV?
Dr Vincent Mallet
Université Paris Descartes, France

1730–1800 Keynote Lecture: Global Issues in HCV

Elimination of HCV: a reality?
Dr Gail Matthews
University of New South Wales, Australia

Gilead Sciences have made a contribution towards the funding of this lecture. Gilead Sciences have had no involvement with the selection of the speaker or content of this lecture.

1800 Case presentation prize and close by the Chair of the British Viral Hepatitis Group
Dr Andrew Ustianowski
North Manchester General Hospital
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830–1830</td>
<td>Registration and exhibition open</td>
<td></td>
</tr>
<tr>
<td>0855–0900</td>
<td>Welcome Address by the Chair of the British HIV Association</td>
<td>Dr David Asboe, Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td>0900–1000</td>
<td>ViiV Healthcare UK Satellite Symposium (See page 14 for further information)</td>
<td></td>
</tr>
<tr>
<td>1000–1030</td>
<td>BHIVA Foundation Lecture</td>
<td>Chair: Dr David Asboe, Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td>1030–1100</td>
<td>Morning coffee</td>
<td></td>
</tr>
<tr>
<td>1100–1200</td>
<td>BHIVA Guidelines Session</td>
<td>Chairs: Dr Duncan Churchill, Royal Sussex County Hospital, Brighton, Dr Adrian Palfreeman, Leicester Royal Infirmary</td>
</tr>
<tr>
<td>1200–1230</td>
<td>BHIVA Audit Session</td>
<td>Chair: Dr Andrew Freedman, Cardiff University School of Medicine</td>
</tr>
<tr>
<td>1230–1400</td>
<td>Lunch and Lunchtime Workshops</td>
<td></td>
</tr>
<tr>
<td>1240–1325</td>
<td>BHIVA Lunchtime Workshop (Abbey, Fourth Floor)</td>
<td>Clinico-pathological case presentations</td>
</tr>
<tr>
<td></td>
<td>Facilitators: Dr Ula Mahadeva, St Thomas’ Hospital, London, Dr Melinda Tenant-Flowers, Retired Consultant in HIV and Sexual Health Medicine</td>
<td></td>
</tr>
</tbody>
</table>
A difficult case to get your head around
Dr Charles Williams
King’s College Hospital, London

Dressed to the 16’s
Dr Emily Chung
Mortimer Market Centre, London

TB or not to be
Dr Hardeep Kang
Blackpool Hospitals NHS Foundation Trust

1255–1355
Janssen Lunchtime Workshop (Rutherford, Fourth Floor) (See page 14 for further information)

1400–1500
BHIVA Plenary Session 1
Chairs: Dr Chloe Orkin
Barts Health NHS Trust, London
Dr Ann Sullivan
Chelsea and Westminster Hospital, London

HIV, STIs, HCV – how can better commissioning improve outcomes?
Professor Simon Barton
Chelsea and Westminster Hospital, London

BHIVA Primary Care Project
Dr Maryam Shahmanesh
UCL Institute of Epidemiology and Health Care, London

1500–1600
BHIVA Plenary Session 2
Chairs: Dr Iain Reeves
Homerton University Hospital, London
Professor Caroline Sabin
University College London

Testing and treatment of HIV within 24 hours: is it viable?
Dr Nneka Nwokolo
Chelsea and Westminster Hospital, London

Long-acting treatment with antiretrovirals
Professor Saye Khoo
University of Liverpool

1600–1630
Afternoon tea

1630–1730
BHIVA Plenary Session 3
Chairs: Professor Lucy Dorrell
University of Oxford
Dr Gabriel Schembri
Manchester Centre for Sexual Health

PrEP: the politics and practicalities of implementation
Dr Laura Waters
Mortimer Market Centre, London

Engagement and the HIV cascade of care
Professor Tim Rhodes
London School of Hygiene and Tropical Medicine

1730–1830
Pfizer Satellite Symposium (See page 14 for further information)

1830–1930
Drinks Reception
FRIDAY 14 OCTOBER 2016

All sessions to be held in the Fleming, Third Floor, QEII Centre unless otherwise stated.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>0815–1440</td>
<td>Registration and exhibition open</td>
</tr>
<tr>
<td>0900–1000</td>
<td><strong>Gilead Sciences Satellite Symposium</strong> <em>(See page 14 for further information)</em></td>
</tr>
<tr>
<td>1000–1030</td>
<td><strong>Gazzard Lectureship in HIV Medicine</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr David Asboe</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td><strong>HIV remission: viral suppression in the absence of ART</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Sarah Fidler</td>
</tr>
<tr>
<td></td>
<td><em>Imperial College Healthcare NHS Trust, London</em></td>
</tr>
<tr>
<td>1030–1040</td>
<td><strong>BHIVA Awards Ceremony</strong></td>
</tr>
<tr>
<td>1040–1110</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1110–1140</td>
<td><strong>CHIVA Plenary Lecture</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Amanda Williams</td>
</tr>
<tr>
<td></td>
<td><em>London North West Healthcare NHS Trust</em></td>
</tr>
<tr>
<td></td>
<td><strong>HIV gene therapy</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Waseem Qasim</td>
</tr>
<tr>
<td></td>
<td><em>Great Ormond Street Hospital, London</em></td>
</tr>
<tr>
<td>1140–1310</td>
<td><strong>BHIVA Best Practice Management Session</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Professor Brian Angus</td>
</tr>
<tr>
<td></td>
<td><em>University of Oxford</em></td>
</tr>
<tr>
<td></td>
<td>Dr Adrian Palfreeman</td>
</tr>
<tr>
<td></td>
<td><em>Leicester Royal Infirmary</em></td>
</tr>
<tr>
<td></td>
<td><strong>Investigating general liver disease/transaminitis</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Emmanuel Tsokachzis</td>
</tr>
<tr>
<td></td>
<td><em>University College London</em></td>
</tr>
<tr>
<td></td>
<td><strong>Managing cryptococcal meningitis</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Tom Harrison</td>
</tr>
<tr>
<td></td>
<td><em>St George’s Healthcare NHS Trust, London</em></td>
</tr>
<tr>
<td></td>
<td><strong>Frailty</strong></td>
</tr>
<tr>
<td></td>
<td>Dr John Soong</td>
</tr>
<tr>
<td></td>
<td><em>Imperial College Healthcare NHS Trust, London</em></td>
</tr>
<tr>
<td>1310–1340</td>
<td><strong>BHIVA Annual General Meeting</strong> <em>(members only)</em></td>
</tr>
<tr>
<td>1310–1440</td>
<td>Lunch and Lunchtime Workshops</td>
</tr>
<tr>
<td>1345–1430</td>
<td><strong>BHIVA Lunchtime Workshop</strong> <em>(Abbey, Fourth Floor)</em></td>
</tr>
<tr>
<td></td>
<td><strong>Pregnancy and breastfeeding case presentations</strong></td>
</tr>
<tr>
<td></td>
<td>Facilitators: Dr Yvonne Gilleece</td>
</tr>
<tr>
<td></td>
<td><em>Royal Sussex County Hospital, Brighton</em></td>
</tr>
<tr>
<td></td>
<td>Dr Liat Sarner</td>
</tr>
<tr>
<td></td>
<td><em>Barts Health NHS Trust, London</em></td>
</tr>
<tr>
<td></td>
<td><strong>Challenges of breastfeeding, where to draw the line</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Seema Malik</td>
</tr>
<tr>
<td></td>
<td><em>Royal Bournemouth Hospital</em></td>
</tr>
<tr>
<td></td>
<td><strong>Pregnancy in HIV-2 infection</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Kanch Seneviratne</td>
</tr>
<tr>
<td></td>
<td><em>Nottingham University Hospitals</em></td>
</tr>
</tbody>
</table>
FRI DAY 1 4 O C T O B E R  2 0 1 6

Primary or reactivation?
Dr Martin Lechelt
Orsett Hospital, Grays, Essex

1440–1540
BHIVA Community Symposium

Chairs: Dr David Chadwick
James Cook University Hospital, Middlesbrough
Mr Paul Clift
King’s College Hospital NHS Foundation Trust

What are the effects of ‘austerity’ on the HIV population?
Local perspective: two cases of PLWHIV who have been affected by ‘austerity’
Ms Marie Rousseau
King’s College Hospital, London

National perspective: the current health of UK-based HIV/AIDS organisations and the effects
of ‘austerity’
Mr Andrew Dalton
University of Sunderland

International commitments: ‘austerity’ and ending AIDS by 2030
Mr Bryan Teixeira
European AIDS Treatment Group (EATG)

1540–1640
BHIVA Clinical Conundrums

Chair: Dr Mas Chaponda
Royal Liverpool University Hospital

Panellists: Professor Mark Bower
Chelsea and Westminster Hospital, London
Professor Clifford Leen
Western General Hospital, Edinburgh
Dr Melinda Tenant-Flowers
Retired Consultant in HIV and Sexual Health Medicine

First-line treatment failure
Dr Nicola Mackie
Imperial College Healthcare NHS Trust, London

Management of diabetes
Professor Karim Meeran
Imperial College Healthcare NHS Trust, London

Opportunistic infections
Dr Ed Wilkins
North Manchester General Hospital

1640–1645
Case presentation prizes and close by the new Chair of the British HIV Association
Dr Chloe Orkin
Barts Health NHS Trust, London
### Friday 14 October 2016

**Please read the CHIVA Parallel Sessions programme in conjunction with the BHIVA Autumn Conference programme.**

All sessions to be held in the Abbey, Fourth Floor, QEII Centre unless otherwise stated.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0815–1440</td>
<td><strong>Registration and exhibition open</strong></td>
</tr>
<tr>
<td>0855–0900</td>
<td><strong>Welcome Address</strong> by the Chair of the Children's HIV Association</td>
</tr>
<tr>
<td></td>
<td>Dr Amanda Williams</td>
</tr>
<tr>
<td></td>
<td>London North West Healthcare NHS Trust</td>
</tr>
<tr>
<td>0900–1040</td>
<td><strong>CHIVA Parallel Session 1</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Tomás Campbell</td>
</tr>
<tr>
<td></td>
<td><strong>Consultant Clinical Psychologists in Private Practice</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Fiona Shackley</td>
</tr>
<tr>
<td></td>
<td><strong>Sheffield Children's Hospital</strong></td>
</tr>
<tr>
<td>0900–0940</td>
<td><strong>Achieving well-being for young people: young people's experiences and clinical responses; remaining engaged with young people who disengage</strong></td>
</tr>
<tr>
<td></td>
<td>Ms Amanda Ely</td>
</tr>
<tr>
<td></td>
<td><strong>Children's HIV Association</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Caroline Foster</td>
</tr>
<tr>
<td></td>
<td><strong>Imperial College Healthcare NHS Trust, London</strong></td>
</tr>
<tr>
<td>0940–1010</td>
<td><strong>Showing of a CHIVA young people’s film</strong></td>
</tr>
<tr>
<td>1010–1040</td>
<td><strong>Psychological coping strategies: child and adolescent mental health</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Jackie Nicholson</td>
</tr>
<tr>
<td></td>
<td><strong>Clinical Psychologist, Manchester</strong></td>
</tr>
<tr>
<td>1040–1110</td>
<td><strong>Morning coffee</strong></td>
</tr>
<tr>
<td>1110–1140</td>
<td><strong>CHIVA Plenary Lecture</strong> Fleming, Third floor (See page 10 for further details)**</td>
</tr>
<tr>
<td></td>
<td><strong>HIV gene therapy</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Waseem Qasim</td>
</tr>
<tr>
<td></td>
<td><strong>Great Ormond Street Hospital, London</strong></td>
</tr>
<tr>
<td>1150–1310</td>
<td><strong>CHIVA Parallel Session 2</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Jolanta Bernatoniene</td>
</tr>
<tr>
<td></td>
<td><strong>Bristol Royal Hospital for Children</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Katja Doerholt</td>
</tr>
<tr>
<td></td>
<td><strong>St George's Hospital, London</strong></td>
</tr>
<tr>
<td>1150–1210</td>
<td><strong>CHIVA Projects update</strong></td>
</tr>
<tr>
<td>1210–1230</td>
<td><strong>CHIVA Youth Committee session</strong></td>
</tr>
<tr>
<td>1230–1310</td>
<td><strong>Developments around PrEP</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Steve Taylor</td>
</tr>
<tr>
<td></td>
<td><strong>Birmingham Heartlands Hospital</strong></td>
</tr>
<tr>
<td>1310–1340</td>
<td><strong>BHIVA Annual General Meeting</strong> (members only)**</td>
</tr>
<tr>
<td>1310–1440</td>
<td><strong>Lunch and Lunchtime Workshops</strong></td>
</tr>
</tbody>
</table>
### CHIVA PARALLEL SESSIONS 2016

**Friday 14 October 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1440–1505</td>
<td>CHIVA Parallel Session 3</td>
<td>Chairs: Dr Alasdair Bamford&lt;br&gt;Great Ormond Street Hospital, London&lt;br&gt;Dr Anna Turkova&lt;br&gt;Imperial College Healthcare NHS Trust, London</td>
</tr>
<tr>
<td>1440–1505</td>
<td>New antiretroviral drugs on the horizon</td>
<td>Mrs Kate Gandhi&lt;br&gt;Birmingham Heartlands Hospital</td>
</tr>
<tr>
<td>1505–1530</td>
<td>Talking about HIV to a young person with learning difficulties</td>
<td>Mrs Yvonne Vaughan-Gordon&lt;br&gt;Birmingham Heartlands Hospital</td>
</tr>
<tr>
<td>1530–1555</td>
<td>AALPHI update</td>
<td>Dr Ali Judd&lt;br&gt;MRC Clinical Trials Unit at UCL, London</td>
</tr>
<tr>
<td>1555–1625</td>
<td>HIV cure research agenda</td>
<td>Professor Nigel Klein&lt;br&gt;University College London</td>
</tr>
<tr>
<td>1625–1655</td>
<td>Stigma and sexual health: Developing coping strategies; when to worry and when to refer</td>
<td>Ms Claire McCausland&lt;br&gt;University of Central Lancashire</td>
</tr>
<tr>
<td>1655</td>
<td>Close by the Chair of the Children’s HIV Association</td>
<td>Dr Amanda Williams&lt;br&gt;London North West Healthcare NHS Trust</td>
</tr>
</tbody>
</table>
PROGRAMME OF SATELLITE SYMPOSIA
AND SPONSORS’ LUNCHEON WORKSHOPS

**W E D N E S D A Y  1 2  O C T O B E R**

1130–1230  **Gilead Sciences Satellite Symposium (Churchill, Ground Floor)**
Simple HCV therapy – transforming the epidemic  
Chair: Dr Andrew Ustianowski  
North Manchester General Hospital
The journey to pan-genotypic HCV therapy options  
Dr Mas Chaponda  
Royal Liverpool University Hospital
Impacting the prevalence – the way forward  
Dr Laura Waters  
Mortimer Market Centre, London
Panel discussion

**T H U R S D A Y  1 3  O C T O B E R**

0900–1000  **ViiV Healthcare UK Satellite Symposium (Fleming, Third Floor)**
HIV in women: science, stigma and society  
Chair: Dr Annemiek de Ruiter  
ViiV Healthcare UK and Guy’s and St Thomas’ NHS Foundation Trust, London
Speakers  
Dr Paul Benn  
ViiV Healthcare UK and Mortimer Market Centre, London
Dr Sara Paparini  
London School of Hygiene and Tropical Medicine
Mrs Paula Evenden  
Dragonfly Collective

1255–1355  **Janssen Lunchtime Workshop (Rutherford, Fourth Floor)**
Tailoring care: how and when to use different ARVs to address diverse patient needs  
Chair: Dr Anton Pozniak  
Chelsea and Westminster Hospital, London
Speaker  
Dr Marta Boffito  
Chelsea and Westminster Hospital, London

1730–1830  **Pfizer Satellite Symposium (Fleming, Third Floor)**
The journey of accessing pneumococcal vaccinations – the path, the hurdles and the potential solutions  
Chair: Professor Anna Maria Geretti  
University of Liverpool
Co-chair: Dr George Kassianos  
British Global & Travel Health Association and Ringmead Medical Practice
Dr David Chadwick  
James Cook University Hospital, Middlesbrough
Dr Catherine Heffernan  
NHS England (London Region) and London School of Hygiene and Tropical Medicine

**F R I D A Y  1 4  O C T O B E R**

0900–1000  **Gilead Sciences Satellite Symposium (Fleming, Third Floor)**
Achieving a balance: planning ahead for the real world challenges we face in HIV  
Chair: Dr Iain Reeves  
Homerton University Hospital, London
Speakers  
Dr Christoph Spinner  
Technical University of Munich, Germany
Dr Paddy Mallon  
Mater Misericordiae University Hospital, Dublin, Ireland
Odefsey® is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤100,000 HIV-1 RNA copies/mL.

Descovy® is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type-1 (HIV-1).

Genvoya® is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.

Prescribing information for Odefsey®, Descovy® and Genvoya® is available overleaf.

Job number: FTAF/UK/16-06/MI/1177(1)
Date of preparation: August 2016
TAF, tenofovir alafenamide
**GENVOYA® PRESCRIBING INFORMATION**

Consult the Summary of Product Characteristics (SPC) before prescribing. GENVOYA® etravirine 150mg/cobicistat 150mg/emericitabine 200mg/ tenofovir alafenamide 10mg film coated tablets. Prescription for treatment of HIV-1 infection in adults & adolescents (aged 12 years & older weighing at least 35 kg). Dosage: Adults & adolescents (aged 12 years & older weighing at least 35 kg): One tablet, once daily, orally & whole meal. Safety & efficacy has not been established. Elderly: mild/moderate hepatic impairment: no dose adjustment required. Severe hepatic impairment: not recommended. Elderly: No dose adjustment required. Severe hepatic impairment: not recommended. Contraindications: hypersensitivity to the active substances or to any excipients. Warnings & Precautions: Should not be co-administered with medicines containing tenofovir disoproxil (as fumarate), lamivudine or adefovir for treatment of HBV infection. Patients with galactose intolerance, Lapp lactose deficiency & glucose-galactose malabsorption should not take GENVOYA® etravirine. Headache should be used either a hormonal contraceptive containing at least 150 µg ethinyloestradiol or another contraceptive & have high first pass metabolism are most susceptible to large decreases in concentrations leading to a reduced therapeutic effect of Genvoya. Cobicistat is a substrate of CYP3A & is a substrate & have high first pass metabolism are most susceptible to large decreases in concentrations leading to a reduced therapeutic effect of Genvoya. Concomitant use of a CYP3A inhibitor may result in increased plasma concentrations of tenofovir alafenamide & genetic factors. Patients with tenofovir reduced in the body may be affected by the activity of OATP1B1 & OATP1B3. Pregnancy & lactation: Use in pregnancy only if potential benefit justifies the potential risk to the foetus. It should not be used during breast-feeding. No side effects: Refer to SPC for full information regarding side effects. Very rare (<1/1000 to <1/100): anaemia, anaphylaxis, dyspepsia, headache, dizziness, diarrhoea, vomiting, abdominal pain, flatulence, abnormal dreams, rash & fatigue. Uncommon (<1/100 to <1/10): anaemia, depression, dyspepsia, abnormal dreams, sleep disorders, mood, convulsions, abdominal pain, vomiting, increased lipase, abdominal discomfort, dry mouth, fatigue, abnormal dreams, rash & fatigue. Rare (<1/1000 to <1/100): anaemia, arthralgia, dyspepsia, angioedema & pruritus. Laboratory tests: P: Haematology: WBC, Hb, PCV, platelet count, SGPT, SGOT, albumin, cholesterol, triglycerides, bilirubin, alkaline phosphatase, creatinine, calcium, phosphate, uric acid, glucose, TSH. Co-factors are available at: https://www.medicines.org.uk/emc/medicine/26751. Co-factors are available at: https://www.medicines.org.uk/emc/medicine/26751. ABBREVIATIONS: HIV = human immunodeficiency virus; HBV = hepatitis B virus.
BHIVA Autumn Conference: 13–14 October 2016

Your registration fee gives access to the scientific sessions of the BHIVA Autumn Conference and the CHIVA Parallel Sessions, including satellite symposia. All refreshments and lunches throughout the conference are included in the registration fee.

The Parallel Sessions are preceded by the CHIVA Dinner at Jamie’s Italian, Victoria from 2000 on Thursday 13 October for those who have booked tickets and paid the necessary fee.

BHIVA Lunchtime Workshops

Places are limited and will be restricted to 80 delegates per workshop. Places will be available on site, on a first-come, first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop.

Each workshop will begin promptly and refreshments will be provided for delegates attending these sessions.

Prizes and awards

The Don Jeffries BHIVA Research Award
BHIVA created this award in honour of the late Professor Don Jeffries. This will be awarded for the highest-scoring application, as judged by the BHIVA Research Awards Judging Panel, from the 11 applications submitted for the 2016 BHIVA Research Awards. The award will be presented in the Lecture Theatre at the BHIVA Awards Ceremony at 1030–1040 on Friday 14 October 2016.

BHIVA Best HIV/Hepatitis Co-infection Case Presentation
A prize will be awarded to the presenter of the best case as part of the Difficult HIV/Hepatitis Co-infection Case Presentation Session to be held at the Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection in collaboration with BVHG.

BHIVA Best Clinico-pathological and Best pregnancy and breastfeeding case presentations
A prize will be awarded to the presenter of the best case for each of the above workshops.

Drinks Reception

The Drinks Reception immediately follows the conference programme at 1830–1930 on Thursday 13 October and will take place in the exhibition area located in the Britten on the Third Floor.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will receive CPD credit at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, social events and satellite symposia). The conference will be allocated a maximum of 6 CPD credits per conference day.

<table>
<thead>
<tr>
<th>CPD Accreditation: Credits attributed and unique reference number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-Infection</td>
</tr>
<tr>
<td>BHIVA Autumn Conference including CHIVA Parallel Sessions</td>
</tr>
<tr>
<td>CHIVA Parallel Sessions only</td>
</tr>
</tbody>
</table>

BHIVA Community Registration
BHIVA has supported free registrations for over 50 community representatives to attend the conference.

BHIVA Registration Scholarships
BHIVA Registration Scholarships have been made available to 10 delegates who are doctors and who are retired, not working or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or post-graduate work. The scholarships cover the conference registration fee.

Cloakroom
A staffed cloakroom is available at the QEII Centre. All belongings are left at the owner’s risk. The QEII Centre and the British HIV Association do not accept responsibility for the loss of, or damage to, delegates’ personal property stored in the cloakroom areas.
Conference venue

QEI Centre
Broad Sanctuary · Westminster · London SW1P 3EE · ☎ +44 (0)20 7222 5000 · www.qeiicc.co.uk

The conference venue is a short walk from Westminster or St James’s Park underground stations. Please see the map for the location of these stations in relation to the QEI Centre.

Westminster and St James’s Park underground stations are easily accessible from King’s Cross, St Pancras (Eurostar) and Victoria main-line rail stations and can be accessed by the Jubilee line or the Circle and District lines. The journey from these main-line stations to Westminster or St James’s Park underground stations takes approximately 10 minutes.

There are also good links to the city centre from both Heathrow and Gatwick airports. Journeys by either Heathrow or Gatwick Express take about 1 hour.

There are four car parks near to the conference venue. For further information please visit www.ncp.co.uk

Please note that the conference venue is located within the London Congestion Charge Zone.
PLENARY SPEAKER BIOGRAPHIES

David Asboe is Clinical Director of HIV Medicine and Sexual Health at Chelsea and Westminster Hospital, London. He has been Chair of the British HIV Association since 2013 and is also Convenor of the Diploma in HIV Medicine exam run by the Worshipful Society of Apothecaries.

Simon Barton is a Consultant HIV and GUM Physician at the Chelsea and Westminster Hospital NHS Foundation Trust. He is Associate Medical Director for Integrated Care, previously being Clinical Director HIV, GUM, Pathology and Dermatology for 18 years until 2015. He was the first Chair of the HIV CRG for 3 years and is now Clinical Chair of the Blood and Infection National Programme of Care Board at NHS England.

Sanjay Bhagani is a Consultant Physician in Infectious Diseases and HIV Medicine at the Royal Free Hospital, London and Honorary Senior Lecturer in Infectious Diseases at University College London. He established and is the current lead of a multi-disciplinary HIV/hepatitis co-infection service at the Royal Free and is the current Chair of BHIVA’s Viral Hepatitis Group. He serves on the HIV/hepatitis guidelines subcommittees for both BHIVA and the European AIDS Clinical Society and is also on the editorial boards of AIDS Research and Therapy and BMC Hepatology, Medicine and Policy and is a trustee at AIDSOrphan.

Michael Brady is a Consultant in Sexual Health and HIV at King’s College Hospital, London and the Medical Director for Terrence Higgins Trust. He has a particular interest in HIV testing and prevention of transmission, and has been involved in a number of projects to develop and evaluate novel HIV testing strategies, including community and outreach point-of-care testing, on-line home HIV and STI sampling, and HIV self-testing.

Ruth Byrne is a Specialty Registrar in GU and HIV Medicine. She is a member of the BHIVA Audit subcommittee and worked on the national audit of HIV late diagnoses. She is currently working as a Clinical Research Fellow at the Institute of Liver Studies, Kings College Hospital with a research interest in HIV/hepatitis B co-infection.

Andrew Dalton is a Lecturer in Social Sciences at the University of Sunderland, with research interests around HIV and AIDS, social inequalities, life histories, LGBT issues and the voluntary sector. Drew has over sixteen years’ experience within the third sector in a range of research, management and support roles. He is currently the Chair of Thrive North East, as well as the Chair of Live HIV Neutral, an activist network across the UK and the Republic of Ireland, with an aim of tackling HIV-related stigma.

Geoff Dusheiko is Emeritus Professor of Medicine at the Royal Free Hospital and University College London School of Medicine and Consultant Hepatologist at Kings College Hospital London. His research interests include the management and treatment of HCV and HBV and small hepatocellular carcinoma; he has a special interest in research on viral hepatitis, especially viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis and antiviral therapies. An advisor for the NICE, he is an author of the WHO’s HCV guidelines and Director of the Skipton Fund. He is member of the Editorial Board of Journal of Viral Eradication, Co-editor of Alimentary Pharmacology and Therapeutics and has published more than 350 articles in international peer-reviewed journals or books.

Amanda Ely is a qualified social worker specialising in HIV. She began work in the field of children and families and HIV in 1997. Amanda practised as a social worker in London for a number of years before becoming a lecturer in social work at London Metropolitan University. She is an associate lecturer in Childhood Studies for the Open University, and having worked for CHIVA since 2008 she is now the CHIVA manager.

Sarah Fidler is a clinical academic in HIV/GUM at Imperial College London and Imperial College Hospital NHS Trust. She trained as an academic clinical researcher and completed a PhD in laboratory-based immunology in 1998. She also completed specialist training in medicine, and HIV and GUM and has been working in HIV clinical research for the past 20 years. Her main areas of research include the use of ART to prevent transmission and she is co-Principal Investigator of the HPTN071 (PopART) study. In addition, she runs studies testing the role of immediate treatment of acute HIV infection combined with strategic and novel intervention studies and leads the UK CHERUB collaboration on approaches towards a cure for HIV.
Caroline Foster is a Consultant in Adolescent HIV and Infectious Diseases at Imperial College Healthcare NHS Trust and is the clinical lead for transitional care in HIV. Current research studies include, the long-term outcomes for adults born with HIV, co-receptor tropism evolution within perinatal infection, the characterisation of the latent reservoir and the development of in vitro therapeutic vaccines in paediatric HIV. Research/education/guideline development and lecturing includes BHIVA, CHIVA, HYPNet, CHIPS, AALPHI, PENTA, UNICEF and WHO.

Graham Foster is the Professor of Hepatology at Queen Mary University of London and head of the Liver Unit at Barts Health. He has a long-standing interest in the management of patients with chronic viral hepatitis and is the national clinical lead for the Hepatitis C Operational Delivery Networks.

Kate Gandhi has worked at Birmingham Heartlands Hospital as a specialist HIV pharmacist for nearly 10 years. She is an independent prescriber, a member of the Faculty of the Royal Pharmaceutical Society and a past-member of the CHIVA Executive Committee.

Yvonne Gilleece is a Consultant in HIV and Sexual Health at Brighton and Sussex University Hospitals NHS Trust. She has a special interest in HIV and Women and is Steering Group Lead for SWIFT. She is the Lead for HIV in Fertility, Conception and Pregnancy and also specialises in HIV and Hepatology in Brighton. She is Chair of the upcoming BHIVA guidelines on the management of HIV infection in pregnant women and the update of the BHIVA/BASHH sexual and reproductive health guidelines. She regularly publishes clinical research and presents nationally and internationally.

Richard Gilson is a Reader in Sexual Health and HIV at University College London, Head of the Research Department of Infection and Population Health, and Director of the Centre for Sexual Health and HIV Research. Richard’s particular interests include HIV and viral hepatitis co-infection (prevalence, transmission, natural history, immunology and response to treatment), and he is the principal investigator on the STOP-HCV-1 treatment strategy trial at the Mortimer Market Centre. Richard’s other interests include HIV cohort studies and HPV disease.

Tom Harrison is Professor of Infectious Diseases and Medicine and Deputy Director of the Institute for Infection and Immunity at St Georges University of London, and Consultant at St Georges Hospital, London. He trained in infectious diseases in London, and in Boston, USA. He leads a clinical research programme on the prevention and treatment of cryptococcal meningitis, developed first in Thailand, and subsequently across sites in sub-Saharan Africa. He is also involved in Phase II and III trials of chemotherapy for tuberculosis. He has served on the cryptococcal guidelines panels of IDSA, the Southern African HIV Clinicians Society and WHO.

William Irving has been Professor and Honorary Consultant in Virology at the University of Nottingham and Nottingham University Hospitals NHS Trust since 2002. His research interest is in the natural history of hepatitis C virus infection. He co-chairs HCV Research UK, a multi-centre consortium creating a national cohort, clinical database and biobank of 10,000 patients infected with HCV. He is a keen bridge player, and being Leeds born-and-bred, has a passion for the fortunes of Leeds United and Leeds Rhinos.

Ali Judd is an epidemiologist at the MRC Clinical Trials Unit at UCL. She co-leads the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC), and leads the UK/Irish CHIPS, CHIPS+ and AALPHI cohorts. She also contributes to the Collaborative Initiative for Paediatric HIV Education & Research (CIPHER) Cohort collaboration.

Saye Khoo is Professor in the Institute of Translational Medicine at the University of Liverpool. He combines practise in Infectious Diseases at the Royal Liverpool University Hospital (chairing the Mersey, Cheshire & N Wales HIV Network), with leading an active research programme in infection pharmacology, focusing on HIV, and more recently tuberculosis and hepatitis C. Research is guided by clinical need, and integrates clinical pharmacokinetics with molecular pharmacology through quantitative modelling approaches. Two web-based prescribing support tools for managing drug interactions (www.hiv-druginteractions.org and www.hep-druginteractions.org) and accompanying smartphone Apps are widely utilised in clinical practice.
PLENARY SPEAKER BIOGRAPHIES

Nigel Klein is a Professor and Consultant in Paediatric Infectious Diseases and Immunology at Great Ormond Street Children’s Hospital, London, the Institute of Child Health, University College London and at the African Health Research Institute in South Africa. He has worked in the field of infectious diseases for many years with particular interests in meningitis, sepsis, innate immunity, premature labour and HIV. He has been a member of several national and international boards and is a member of the PENTA Immunology and Virology committee. He has published more than 300 papers and supervised more than 30 PhD students of whom more than half have been Clinical Fellows.

Ranjababu Kulasegaram (Babu) is a Consultant in HIV/GU Medicine at St Thomas’ Hospital and leads the HIV Treatment Advice Clinic, with special interests in HIV/hepatitis, haemophilia/HIV infection, HIV/neurocognitive function and HIV inpatient management. Babu is committed to enhancing BHIVA’s educational activities through his involvement as a course director for the BHIVA General Medicine Course, his contributions as one of the leads for the Diploma in HIV Medicine Revision Course, and as a current member of the BHIVA Hepatitis Society and EHHC Programming committee. Babu is an examiner for the Diploma in HIV Medicine, immediate past Chair of the BHIVA Hepatitis Society and also served as Vice Chair of the BHIVA Education and Scientific subcommittee.

Jordan Lake is Associate Professor at the University of Texas Health Science Center McGovern School of Medicine in Houston, TX. She completed both medical school and Internal Medicine residency at Baylor College of Medicine in Houston, Texas, followed by an Infectious Diseases fellowship at the University of California, Los Angeles. Her research focuses on the treatment of metabolic and ageing-related complications of HIV and antiretroviral therapy.

Nicola Mackie is a Consultant Physician and Head of Speciality for HIV at Imperial College Healthcare NHS Trust. Her research was in the field of HIV-1 drug resistance and she runs the weekly Virtual Clinic. She is also the Clinical Lead for the HIV Women’s Service at Imperial. She is involved with writing national guidelines, examining for dipHIV and teaching for BASHH and EACS. She has recently been elected as a Trustee member of the BHIVA Executive committee.

Ula Mahadeva is a Consultant Histopathologist at Guy’s and St Thomas’ NHS Foundation Trust where her areas of subspecialisation are gastrointestinal histopathology, gynaecological and non-gynaecological cytology, consented and maternal death autopsies, and infectious disease histopathology. She is known within the department and region for her enthusiasm for teaching and training, including helping trainees with preparation for the FRCPath examination, and is an RCPPath examiner.

Vincent Mallet has worked on basic and clinical aspects of liver diseases since 1999. His main areas of interest and contributions include burden of viral hepatitis and outcomes of treatments, viral hepatitis in immunocompromised hosts, immunopathogenesis of HCV, HBV and HEV infections, novel immunomodulatory therapies for cancer and hepatocellular carcinoma, big-data to describe the natural courses of diseases. He has published many articles in international peer-reviewed journals and is an Associate Editor for the *Journal of Antimicrobial Chemotherapy*, and a reviewer for several journals.

Gail Matthews is trained as an HIV/sexual health specialist in London and an Infectious diseases Physician in Australia. She currently holds a position as a clinical academic in HIV/Infectious Diseases at St Vincent’s Hospital and is an Associate Professor in the Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW. She completed her PhD on therapeutic strategies in HIV/HBV confection and has a particular interest in HIV/ viral hepatitis confection including acute hepatitis C, antiviral resistance and marginalised populations.

Claire McCausland is a Senior Lecturer at the University of Central Lancashire, where she is Course Leader for the BSc (Hons) Sexual Health Studies programme. She is an NMC-registered Nurse and has been practising in sexual health and HIV care and management since 2003; Claire’s role prior to joining the University was in working in support of vulnerable sexually active under 18-year-olds.
Kaëm Meeran did his undergraduate and postgraduate training in London, and then proceeded to an academic career at Imperial College. He is a Fellow both of the Royal College of Physicians and the Royal College of Pathologists. He has become the Training Programme Director for Metabolic Medicine and Endocrinology in London and is on the Educational Committee for the European Society of Endocrinology. He has over 100 peer-reviewed articles and has published on Cushing’s syndrome, pituitary diseases, and the gut hormone control of food intake and appetite. He runs a successful Endocrinology and Advanced Diabetes training course and is responsible for the training of specialists in endocrinology in London.

Jackie Nicholson is a Clinical Psychologist and has been working with young people and their families with mental health issues for 13 years. Now working with the Paediatric HIV team based at North Manchester District General, she provides psychological assessment and care directly to young people with HIV, as well as supporting their families and carers. Jackie’s work also involves contributing to the paediatric multidisciplinary team, working with schools, social care and voluntary agencies. She uses an integrative approach in her assessments and interventions; however, she is mostly influenced by systemic and family psychotherapy.

Nneka Nwokolo is a Consultant Physician in HIV/GUM at 56 Dean Street, Chelsea and Westminster Hospital. She has a particular interest in HIV prevention and jointly established the first PrEP clinic in the UK. She has been actively involved in the development of guidelines for the monitoring of individuals on generic PrEP and is involved in clinical studies of PrEP and of early treatment of HIV infection. She established the Dean Street cohort, a prospective study of HIV-positive patients at 56 Dean Street, a clinic that makes over 400 new HIV positive diagnoses/year of which 45% are incident infections.

Chloe Orkin is a Consultant Physician and Honorary Reader in HIV Medicine at the Royal London Hospital where her clinical duties include running a busy HIV and HIV/HCV research unit. Her specialist interests are: antiretroviral therapy, hepatitis and oncology. She is Chair Elect of the British HIV Association. She has over 90 peer-reviewed publications and has been a co-author on four BHIVA guidelines. Chloe is the External Examiner to the Diploma in HIV Medicine. She is actively researching ways of implementing HIV and blood-borne virus testing.

Jean-Michel Pawlotsky is Professor of Medicine at the Université Paris-Est. He is the Director of the National Reference Center for Viral Hepatitis B, C and Delta and of the Department of Virology at the Henri-Mondor University Hospital, Créteil, France, and Director of the Academic Department ‘Viruses, Immunity and Cancers (INSERM U955). He was acting Secretary General of EASL and an Associate Editor of both Hepatology and Gastroenterology. He has published over 500 articles and book chapters and is a regular speaker at international meetings.

Frank Post is a consultant physician in HIV Medicine and HIV Research Lead at King’s College Hospital, London. His research is focused on kidney disease in HIV infection and the effects of antiretroviral therapy on kidney and bone. He has published more than 100 papers and been a co-author on several BHIVA guidelines and the British Transplantation Society guidelines for kidney transplantation in patients with HIV.

Waseem Qasim is NIHR Professor of Cell and Gene Therapy at Great Ormond Street Institute of Child Health and Consultant in Paediatric Immunology and Bone Marrow Transplantation. His group is leading delivery T cell therapies in transplantation including lentiviral engineered T cell therapies for leukaemia. In 2015, the successful application of gene-editing technology to treat two infants with leukaemia created headline news. Similar approaches are being developed to confer resistance to HIV, including by co-receptor gene-editing and the transfer of antiviral restriction factors.

Tim Rhodes is a Professor in Public Health Sociology at the London School of Hygiene and Tropical Medicine, and Conjoint Professor of the Sociology of Health at the University of New South Wales. He uses qualitative methods to explore narratives of self and health, including in relation to risk environments mediating HIV, hepatitis C and injecting drug use. His current research focuses on the social relations of access to HIV prevention, treatment and care, including among people who inject drugs in East Africa and among people living with HIV and hepatitis C in the UK.
PLENARY SPEAKER BIOGRAPHIES

Alison Rodger is a Reader in Infectious Diseases at University College London, and Consultant in Infectious Diseases/HIV and Director of Public Health at the Royal Free Hospital in London. Alison is a co-author of BHIVA guidelines on hepatitis co-infection, immunisations and post-exposure prophylaxis. She co-chairs the guideline writing group for PrEP. Her academic interests are HIV transmission, testing and prevention.

Marie Rousseau is a Specialist Practitioner in HIV Welfare and Support based at Kings College Hospital. She works in both in- and out-patient settings, providing welfare and support to individuals, particularly those with complex needs. She manages integrated care pathways, overseeing service use across community health, social care and voluntary sectors, focusing on engagement in care. She facilitates the multidisciplinary team meetings, working very closely alongside the HIV community team, HIV mental team and the patient representative. She has considerable experience of working with marginalised groups of people, in particular those who have experienced stigma, prejudice and discrimination, enabling them to address health inequalities through community engagement and empowerment. Her main interests are around HIV service delivery and end-of-life care and she volunteers at St Christopher’s Hospice.

Caroline Sabin is Professor of Medical Statistics and Epidemiology at University College London (UCL) and is Director of the National Institutes for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, a partnership between UCL, Public Health England (PHE) and the London School of Hygiene and Tropical Medicine. Caroline has worked for many years on the analysis of large observational HIV databases with a particular interest in raising awareness of the biases inherent in these databases; she is the principal investigator on the UK CHIC Study, the principal statistician on the D:A:D Study, co-principal investigator on the POPPY Study, and has worked with many other research groups in the UK and elsewhere.

Liat Sarner has been a consultant in Sexual Health and HIV at The Royal London Hospital since 2003 and is Clinical Director of Sexual Health and HIV services across Barts Health NHS Trust. She has a particular interest in HIV and women including conception, pregnancy and menopause, runs the antenatal HIV service and is part of the London HIV pregnancy research group.

Maryam Shahmanesh is a Senior Lecturer in the Centre for Sexual Health and HIV research and an Honorary Consultant in Sexual Health and HIV Medicine at the Mortimer Market Centre. After graduating in Medicine, Maryam completed her specialist training in Sexual health and HIV medicine. Her academic training, which has complemented her clinical training, includes a degree in Social and Political Science, a Masters in Epidemiology, and a PhD in Clinical Epidemiology.

Ruth Simmons is an epidemiologist with PHE within the Health Protection Research Unit, leading on mapping the cascade of care for blood-borne viruses (BBV) through data linkage. Ruth is also the lead for the sentinel surveillance of BBV testing. Ruth has a Masters in Epidemiology, and has recently completed a PhD estimating HIV incidence in Ukraine, Poland and Estonia. Ruth was also a member of the WHO working group on HIV incidence assays, developing technical guidelines for determining HIV incidence using case-based surveillance data and recent infection testing algorithms.

John Soong is an RCP Clinical Quality Improvement Research and Training Fellow. He is undertaking Doctoral Research with Imperial College London studying risk stratification for Frailty in the Acute Medical Care setting. John is a clinical doctor with joint accreditation in the subspecialties of Acute Medicine and Intensive Care Medicine. He is a member of the Patient Safety Committee at the Royal College of Physicians and was a member of the data workstream for the Future Hospital Commission. He has been involved in a number of national quality improvement initiatives including HQIP Audit of Audits, FRAILsafe and Atrial Fibrillation on the Acute Medical Unit.

Steve Taylor is the Lead HIV Consultant at Birmingham’s Heartlands Hospital and Honorary Senior Lecturer at the University of Birmingham. He has been an elected member of the BHIVA Executive committee and been a member of scientific committee for many international conferences. He sits on the Medical Advisory boards for HIV i-Base and AIDs Treatment Update, and teaches and lectures regularly to HIV-positive patient groups, as well as delivering four national courses on HIV drug resistance and pharmacology. He is Medical Director of the national HIV testing awareness charity, Saving Lives, as well as being Tri Service Consultant Advisor to HM Armed Forces and chairing the clinicians’ group for the Department of Health development of the HIV outpatient tariff. He is West Midlands Media representative for BASHH and regularly appears on television and radio to comment on issues pertaining to sexual health and HIV.
Bryan Teixeira has over 25 years’ experience leading on community-based sexual health and HIV programmes. He was the CEO of NAZ (London) for 11 years and UK National Focal Point for AIDS and Mobility Europe for 10 years. He also served for 3 years on the NGO Delegation at the UNAIDS Programme Coordinating Board as the main Delegate for Europe. Currently, Bryan works as a freelance consultant based in Carcassonne, France, and is the Chair of the Policy Working Group of the European AIDS Treatment Group (EATG), Brussels.

Melinda Tenant-Flowers is a retired Consultant in HIV/Sexual Health at King’s College Hospital, London. Her research interests included HIV oncology, HIV testing and educational assessment. She has contributed to three BHIVA guidelines. She has an MSc in Medical Education, is lead for BHIVA e-Learning CPD and a member of the BHIVA Education/Scientific, Conferences and Website Subcommittees. She has been an examiner for the Diploma in HIV Medicine since its foundation, was Convenor of the Diploma in Genitourinary Medicine, STC co-chair and ARCP representative (London) and contributed to the latest HIV curriculum revision for the SAC and RCP.

Emma Thomson is an Infectious Diseases Physician and Clinical Senior Lecturer in Virology in Glasgow. She runs a co-infection treatment clinic in Glasgow and runs a laboratory funded by the Wellcome Trust and the MRC that carries out research into HCV immunity using next-generation sequencing and functional B and T cell assays. She is a member of the WHO HCV treatment guidelines committee.

Alicia Thornton has worked in HIV surveillance and research since 2005. Her previous research interests have included HIV testing and sexual behaviour. In 2011 Alicia joined University College London to work on the UK CHIC study with a particular focus on hepatitis co-infection.

Mark Thursz is Professor of Hepatology at Imperial College where he is head of the Digestive Diseases Division and also Lead Clinician for Hepatology at St Mary’s Hospital, London. His clinical interests are in viral hepatitis, alcoholic and fatty liver disease.

Emmanuel Tsochatzis is a Senior Clinical Lecturer and Consultant Hepatologist at the University College London Institute for Liver and Digestive Health, Royal Free Hospital, London. He was the recipient of the Rising Star in Gastroenterology prize by the UEG and the EASL Physician Scientist Fellowship in 2014. His research interests include non-alcoholic fatty liver disease, cirrhosis and portal hypertension, and non-invasive assessment of liver fibrosis. His work on the cost-effectiveness of non-invasive fibrosis tests has informed the WHO guidelines on diagnosis and treatment of both HBV and HCV. He has published more than 120 articles in peer-reviewed journals.

Andrew Ustianowski is a Consultant and Research Lead at the Regional Infectious Diseases Unit, Manchester, and Chair of the British Viral Hepatitis Group. He is a co-author of co-infection and other national guidance, and lectures widely on HIV, hepatitis and associated subjects.

Yvonne Vaughan-Gordon is the Lead Nurse for the West Midlands Region, the largest Paediatric HIV centre for children outside London. She has been involved in caring for children and their families since 2000, when the first children presented with life-threatening symptoms such as PCP. Children were hospitalised for months on end and treatment regimens were difficult to maintain due to restrictions and undesirable side effects. The survival of these newly diagnosed positive children was very uncertain. However, 16 years later their futures look bright. They are now looking forward and thinking about their own future careers and families. The road at times has been rocky and uncertain but Yvonne is proud to say that she has walked with them, been witness to their courage and tenacity, and looks forward to seeing how much more they can achieve in the future.

Peter Vickerman is a Professor in Infectious Disease Modelling at the University of Bristol. His research focuses on the use of mathematical modelling to help understand the transmission of different infectious diseases and the impact and cost-effectiveness of prevention measures. Specific expertise focuses on the transmission of HIV, HCV and other STIs amongst different high-risk groups including injecting drug users. He has extensive experience of conducting collaborative research with organisations in Asia, sub-Saharan Africa, Eastern Europe and the UK.
Charlotte Warren-Gash is an academic public health doctor. Her main research interest is using linked electronic health records and biological data to investigate the effect of infections on the course of chronic diseases to inform personalised prevention. She has recently been awarded a Wellcome Trust intermediate clinical fellowship at the London School of Hygiene and Tropical Medicine. She also contributes to policy work as a visiting fellow at the Foundation for Genomics and Population Health in Cambridge.

Laura Waters is a Consultant at the Mortimer Market Centre in London where she is HIV and Hepatitis Service Lead. She was Vice-Chair of the 2015 BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy and now chairs this group; she is Vice-Chair of the BHIVA Conferences subcommittee and Chair of the BASHH HIV Special Interest Group. Laura has an MD in antiretroviral simplification and switch, and is Principal Investigator for several first-line and switch studies at Mortimer Market.

Ed Wilkins is an Infectious Diseases Physician at North Manchester General Hospital in the UK, and holds Honorary positions at Manchester and Liverpool Universities. Dr Wilkins trained in infectious diseases in the UK, tropical medicine in Africa, and clinical microbiology and virology with the UK Health Protection Agency. He has been involved with HIV patient care and research since 1982, with particular interests in antiretroviral toxicity, hepatitis and TB co-infection, HIV and the brain, and treatment as prevention. Dr Wilkins is involved in many national executive and advisory committees, including the British HIV Association (BHIVA). He is a co-author on several National Guidelines and is chair of the BHIVA hepatitis co-infection guideline writing committee.

Amanda Williams has been a Consultant Paediatrician and Specialist in Paediatric Infectious Diseases at London North West Healthcare NHS Trust since 2002. She is lead for Paediatric HIV and Tuberculosis. Amanda has previously been Honorary Secretary of CHIVA and Chair of the CHIVA guideline group. She is a co-author of the CHIVA Standards of Care for Infants, Children, and Young People with HIV. She is the current Chair of the Children’s HIV Association.
FORTHCOMING EVENTS

BHIVA General Medicine for HIV Physicians Course
Thursday 3 November 2016
NCVO, London

BHIVA/BVHG Hepatology Highlights
Thursday 24 November 2016
Radisson Blu Hotel, Birmingham

BHIVA World AIDS Day
‘How to Survive a Plague’
Wednesday 30 November 2016
Curzon Soho, London

BHIVA/BASHH Course on Mentoring Skills for Sexual Health/HIV Physician
Friday 9 December 2016
Medical Research Council Head Office, London

BHIVA ‘Best of CROI!’ Feedback 2017
Monday 27 February 2017, London
Tuesday 28 February 2017, Edinburgh
Wednesday 1 March 2017, Wakefield
Thursday 2 March 2017, Cardiff
Tuesday 7 March 2017, Birmingham
Wednesday 8 March 2017, Haydock
Thursday 9 March 2017, Newcastle

23rd Annual Conference of the British HIV Association (BHIVA)
4–7 April 2017
Arena and Convention Centre, Liverpool

BHIVA MAJOR SPONSORS 2016

Bristol-Myers Squibb Pharmaceuticals Ltd
Uxbridge Business Park
Sanderson Road
Middlesex UB8 1DH

Gilead Sciences Ltd
280 High Holborn
London
WC1V 7EE

Janssen
50–100 Holmers Farm Way
High Wycombe
Buckinghamshire HP12 4DP

MSD Ltd
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU

ViiV Healthcare UK Ltd
Stockley Park West
Uxbridge
Middlesex UB11 1BT

BHIVA major sponsors and commercial exhibitors have supported the BHIVA Autumn Conference by purchasing exhibition stand space.

Conference Organiser: Mediscript Ltd,
1 Mountview Court,
310 Friern Barnet Lane, London N20 0LD
T: +44 (0) 20 8369 5380 F: +44 (0)20 8446 9194
E: conferences@bhiva.org
TRIUMEQ®

**Dolutegravir**

**At the Core**

**The Only INI that Offers All of the Following:**

- **Superior Efficacy**
  - in treatment-naïve patients vs Atripla®, darunavir/r
  - and atazanavir (in women) 1-3

- **High Barrier to Resistance**
  - 0 resistance to dolutegravir-based regimens in treatment-naïve trials 4-5

- **Booster-Free Dosing**
  - with few clinically significant drug-drug interactions5

For your treatment-naïve patients... and for patients who may benefit from a change in ART regimen, CHOOSE...

**Prescribing Information**

**Tivicay**

**Dolutegravir 50mg tablets**

See Summary of Product Characteristics before prescribing.

**Indication:** HIV in over 12 years and ≥ 40kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. **Dose:** one tablet once daily with or without food. **Elderly:** Limited data in 65+ yrs. Creatinine clearance < 50ml/min or moderate/severe hepatic impairment: Not recommended. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Conclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with efavirenz without boosted PI), etravirine, nevirapine, tipranavir, boosted tipranavir, carbamazepine, oxcarbazapine, phenytoin, phenobarbital and St John’s Wort. Use with cladribine not recommended. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Caution with metformin: monitor renal function and consider Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with efavirenz requires boosted PI or increased dose of dolutegravir. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for details. Headache, insomnia, sleep disturbances, disorientation, GI disturbance, fatigue, hypersensitivity, anaemia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthralgia, muscle disorders, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. **Basic NHS costs:** 30 tablets: £798.16 EUI/11/14/940/001. MA holder: ViiV Healthcare Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GMSmithKlineK UK Ltd, Stockley Park West, Uxbridge, Middlesex U18 1B1.

TRIUMEQ®

**Dolutegravir**

**In treatment-naïve patients vs Atripla®, darunavir/r and atazanavir (in women) 1-3**

**Efficacy**

**Superior Efficacy**

**High Barrier to Resistance**

**Booster-Free Dosing**

**References:**